Brorphine

Last updated
Brorphine
Brorphine Structure.svg
Legal status
Legal status
Identifiers
  • 3-{1-[1-(4-bromophenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-one
CAS Number
PubChem CID
ChemSpider
KEGG
ChEMBL
Chemical and physical data
Formula C20H22BrN3O
Molar mass 400.320 g·mol−1
3D model (JSmol)
  • CC(C1=CC=C(C=C1)Br)N2CCC(CC2)N3C4=CC=CC=C4NC3=O
  • InChI=1S/C20H22BrN3O/c1-14(15-6-8-16(21)9-7-15)23-12-10-17(11-13-23)24-19-5-3-2-4-18(19)22-20(24)25/h2-9,14,17H,10-13H2,1H3,(H,22,25)
  • Key:CNOFBGYRMCBVLO-UHFFFAOYSA-N

Brorphine is a piperidine-based opioid analgesic compound. [1] [2] Brorphine was originally discovered in a 2018 paper investigating functionally biased opioid compounds, with the intention of finding safer analgesics that produce less respiratory depression than typical opioids. [3] Brorphine was originally reported to be highly biased, with an EC50 of 4.8nM for GTPγS binding and 182nM for β-arrestin recruitment, [3] however a more recent study found no significant bias for any of the compounds tested, including brorphine. [4] Its safety profile in any animal model has never been established. Despite the lack of safety information on the compound, brorphine has been sold as a designer drug since mid-2019, initially being identified in the US Midwest, though it has since been found in 2020 in Belgium. It is related in chemical structure to compounds such as benzylfentanyl and bezitramide, though it is sufficiently structurally distinct to fall outside the formal definition of a "fentanyl analogue" in jurisdictions such as the US and New Zealand which have Markush structure controls over this family of drugs. [4] [5]

Contents

Brorphine was first identified in the U.S. recreational drug supply in July 2020 by the Center for Forensic Science Research and Education (CFSRE) through its NPS Discovery program; however, earlier identifications by the Drug Enforcement Administration (DEA) may have come as early as late 2019. The rise of brorphine in the U.S. can be directly linked to the decline of isotonitazene due to scheduling by the DEA. [6] Brorphine was first implicated in 20 deaths in the U.S., primarily in cases originating from midwest states. Brorphine was commonly found with fentanyl and flualprazolam, a drug combination verified by drug product testing. Brorphine has also been identified in counterfeit opioid pills and tablets. Recently data from CFSRE and NMS Labs show that brorphine has been detected in more than 100 cases as of October 2020. [7] [8] [9]

Legality

Brorphine is not controlled under the Single Convention on Narcotic Drugs from 1961, however could be illegal to sell, to produce, to possess or to consume it in several countries of is sold for human consumption or under the Analogue Acts. In the United States, Brorphine was placed into temporary emergency schedule I for 2 years by the DEA on January 4, 2021 [10] On February 3, 2023, the DEA filed plans in the federal register for permanent placement of Brorphine into schedule I. [11] [12]

See also

Related Research Articles

<span class="mw-page-title-main">Piperidylthiambutene</span> Chemical compound

Piperidylthiambutene (Piperidinohton) is a synthetic opioid analgesic drug from the thiambutene family, which has around the same potency as morphine. Piperidylthiambutene is structurally distinct from fentanyl, its analogues, and other synthetic opioids previously reported. If sold or obtained for the purpose of human consumption it could be considered a controlled substance analogue in some countries such as the US, Australia and New Zealand. Piperidylthiambutene has been sold as a designer drug, first appearing in late 2018.

<span class="mw-page-title-main">Butyrfentanyl</span> Synthetic opioid analgesic

Butyrfentanyl or butyrylfentanyl is a potent short-acting synthetic opioid analgesic drug. It is an analog of fentanyl with around one quarter of its potency. One of the first mentions of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned as N-butyramide fentanyl analog. This document also states that the article describing its clinical effects was published in 1987. It is an agonist for the μ-opioid receptors.

<span class="mw-page-title-main">U-47700</span> Opioid analgesic

U-47700, also known as U4, pink heroin, pinky, and pink, is an opioid analgesic drug developed by a team at Upjohn in the 1970s which has around 7.5 times the potency of morphine in animal models.

<span class="mw-page-title-main">Furanylfentanyl</span> Opioid analgesic

Furanylfentanyl (Fu-F) is an opioid analgesic that is an analog of fentanyl and has been sold as a designer drug. It has an ED50 value of 0.02 mg/kg in mice. This makes it approximately one fifth as potent as fentanyl.

<span class="mw-page-title-main">Acrylfentanyl</span> Opioid analgesic

Acrylfentanyl (also known as acryloylfentanyl) is a highly potent opioid analgesic that is an analog of fentanyl and has been sold online as a designer drug. In animal studies the IC50 (the half maximal inhibitory concentration for acrylfentanyl to displace naloxone) is 1.4 nM, being slightly more potent than fentanyl itself (1.6 nM) as well as having a longer duration of action.

<span class="mw-page-title-main">Metonitazene</span> Chemical compound (analgesic drug)

Metonitazene is an analgesic compound related to etonitazene, which was first reported in 1957, and has been shown to have approximately 1000 times the potency of morphine by central routes of administration, but if used orally it has been shown to have approximately 10 times the potency of morphine.

<span class="mw-page-title-main">Isotonitazene</span> Chemical compound

Isotonitazene is a benzimidazole derived opioid analgesic drug related to etonitazene, which has been sold as a designer drug. It has only around half the potency of etonitazene in animal studies, but it is likely even less potent in humans as was seen with etonitazene. Isotonitazene was fully characterized in November 2019 in a paper where the authors performed a full analytical structure elucidation in addition to determination of the potency at the μ-opioid receptor using a biological functional assay in vitro. While isotonitazene was not compared directly to morphine in this assay, it was found to be around 2.5 times more potent than hydromorphone and slightly more potent than fentanyl.

<span class="mw-page-title-main">Etonitazepyne</span> Chemical compound

Etonitazepyne is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug and linked to numerous cases of overdose.

<span class="mw-page-title-main">ADB-4en-PINACA</span> Chemical compound

ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.

<span class="mw-page-title-main">AP-238</span> Opioid designer drug

AP-238 is an opioid designer drug related to drugs such as azaprocin and bucinnazine, with around the same potency as morphine. It was first discovered in Italy in the 1960s but was never marketed, subsequently appearing on the illicit market around 2020 and being detected in both Slovenia and the USA.

<span class="mw-page-title-main">Butyrylnorfentanyl</span> Synthetic opioid analgesic metabolite

Butyrnorfentanyl or butyrylnorfentanyl is an inactive synthetic opioid analgesic drug precursor. It is an analog of fentanyl.

<span class="mw-page-title-main">Remifentanilic acid</span> Inactive metabolite of remifentanil

Remifentanilic acid is a metabolite of the potent short-acting synthetic opioid analgesic drug remifentanil. It is an analog of fentanyl and remifentanil, but is not active as an opioid in its own right.

<span class="mw-page-title-main">Protonitazene</span> Chemical compound

Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the USA and Australia. It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the USA.

<span class="mw-page-title-main">Butonitazene</span> Chemical compound

Butonitazene is a benzimidazole derivative with opioid effects, which has been sold over the internet as a designer drug. It has relatively low potency compared to many related compounds, and has generally been encountered as a component of mixtures with other substances rather than in its pure form. However, it is still several times the potency of morphine and has been implicated in several cases of drug overdose. Butonitazene is a Schedule I drug in the USA, along with several related compounds.

<span class="mw-page-title-main">Parafluorofuranylfentanyl</span> Chemical compound

para-Fluorofuranylfentanyl is an opioid analgesic that is an analog of fentanyl and has been sold as a designer drug. As with other fentanyl analogues, parafluorofuranylfentanyl has significant side effects including itching, nausea and potentially serious respiratory depression, which can be life-threatening, and it has been linked to numerous deaths from overdose. It falls within the definition of Schedule I drugs in the USA under federal drug analogue legislation, and is specifically listed as a Schedule I drug in North Dakota.

<i>N</i>-Desethylisotonitazene Chemical compound

N-Desethylisotonitazene (Norisotonitazene) is a benzimidazole derivative with potent opioid effects which has been sold as a designer drug. It was first identified as an active metabolite of the related compound isotonitazene, but was unexpectedly found to be similar potency compared to the parent compound, and is among the most potent opioid agonists in this family, around 20 times stronger than fentanyl. It has become an increasingly widespread drug of abuse in its own right, linked to numerous cases of drug overdose,and may be considered an analog of a schedule 1 drug in the US. On October 25 an intent to temporarily schedule Etonitazepipne and N-desethyl Isotonitazene was published. So on November 24 a month after publishing intent, it will most likely be placed in schedule 1.

Utopioids are a class of synthetic opioid analgesic drugs first developed in the 1970s by the pharmaceutical company Upjohn. However, they were never marketed for medical use. Some compounds from this class have been used for scientific research as model kappa opioid receptor agonists. In the mid-2010s, one mu opioid receptor selective compound from this class, U-47700, re-emerged as a designer drug and became widely sold around the world for several years before being banned in various jurisdictions from 2016 onwards. Following the prohibition of U-47700, a number of related compounds have continued to appear on illicit drug markets. They are often marketed online or included as components in mixtures sold under the guise of "street heroin." U-47700 itself is the most potent mu opioid agonist from this class, around 7-10x the potency of morphine. Some other compounds such as 3,4-MDO-U-47700 and N-Ethyl-U-47700 retain similar mu selectivity but with lower potency similar to that of morphine, or have a mixture of mu and kappa mediated effects, such as U-48800. Most utopioid derivatives are however selective kappa agonists, which may have limited abuse potential as dissociative hallucinogens, but do not alleviate withdrawal distress in opioid dependent individuals or maintain addiction in a typical sense. Nevertheless, this has not stopped them from being sold as designer drugs, and a number of these compounds are now banned in many jurisdictions alongside U-47700 itself.

<span class="mw-page-title-main">Etoetonitazene</span> Chemical compound

Etoetonitazene is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is an analogue of etonitazene where the ethoxy group has been extended to ethoxyethoxy. It is less potent than etonitazene itself, but is still a potent opioid agonist with around 50x the potency of morphine, and has been sold as a designer drug since around 2022.

<span class="mw-page-title-main">Flunitazene</span> Designer drug with opioid effects

Flunitazene (Fluonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is one of the least potent derivatives from this class to have appeared as a designer drug, with only around the same potency as morphine, but nevertheless has been sold since around 2020, and has been linked to numerous drug overdose cases.

References

  1. ↑ Grafinger KE, Wilde M, Otte L, Auwärter V (August 2021). "Pharmacological and metabolic characterization of the novel synthetic opioid brorphine and its detection in routine casework". Forensic Science International. 327: 110989. doi:10.1016/j.forsciint.2021.110989. PMID   34509061.
  2. ↑ Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R (April 2021). "DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles". ACS Chemical Neuroscience. 12 (7): 1072–1092. doi:10.1021/acschemneuro.1c00037. PMID   33760580. S2CID   232356192.
  3. 1 2 Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT, et al. (October 2018). "Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias". Journal of Medicinal Chemistry. 61 (19): 8895–8907. doi:10.1021/acs.jmedchem.8b01136. PMC   6386185 . PMID   30199635.
  4. 1 2 Vandeputte MM, Cannaert A, Stove CP (November 2020). "In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances". Archives of Toxicology. 94 (11): 3819–3830. doi:10.1007/s00204-020-02855-7. hdl: 1854/LU-8687070 . PMID   32734307. S2CID   220881657.
  5. ↑ Verougstraete N, Vandeputte MM, Lyphout C, Cannaert A, Hulpia F, Van Calenbergh S, et al. (January 2021). "First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?". Journal of Analytical Toxicology. 44 (9): 937–946. doi:10.1093/jat/bkaa094. hdl: 1854/LU-8671214 . ISSN   0146-4760. PMID   32744605.
  6. ↑ Vandeputte MM, Krotulski AJ, Papsun DM, Logan BK, Stove CP (July 2021). "The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament". Journal of Analytical Toxicology. 46 (2): 115–121. doi: 10.1093/jat/bkab082 . PMID   34233349.
  7. ↑ Krotulski AJ, Papsun DM, Noble C, Kacinko SL, Logan BK (March 2021). "Brorphine-Investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry". Journal of Forensic Sciences. 66 (2): 664–676. doi:10.1111/1556-4029.14623. PMID   33201526. S2CID   226990291.
  8. ↑ Vohra V, King AM, Jacobs E, Aaron C (September 2021). "Death associated with brorphine, an emerging novel synthetic opioid". Clinical Toxicology. 59 (9): 851–852. doi:10.1080/15563650.2021.1879111. PMID   33522844. S2CID   231761916.
  9. ↑ Vandeputte MM et al, The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament. Journal of Analytical Toxicology 2022; 46(2): 115–121. doi : 10.1093/jat/bkab082
  10. ↑ "Federal Register :: Request Access".
  11. ↑ "Federal Register :: Request Access".
  12. ↑ https://public-inspection.federalregister.gov/2023-04364.pdf


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.